TACE术治疗肝癌患者随访研究*

doi:10.3969/j.issn.1672-5069.2016.01.027

Abstract

Lu Jianying, Liu Qun, Zhai Xiaofeng, et al. Transcatheter arterial embolization in treatment of patients with primary liver cancer[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(1): 96-97.

[1] Kas ugai H,Kojima J,Tats uta M,et al. Treatment of hepatocelluar carcinoma by transcatheter arterial embolization combined with intraaterial infusion of a mixture of cisplation and ethiodizedicl. Gastroenterology,1989,97:965-967.
[2] 汤钊猷. 肝癌治疗的“消灭与改造并举”策略. 实用肝脏病杂志,2015,18（2）：113-114.
[3] 俞婷,俞谦,欧希龙,等. 原发性肝癌肝动脉化疗栓塞后严重肝功能失代偿的相关因素分析. 现代医学杂志,2009,2:20.
[4] 韦勇,涂蓉,陈忠明,等. 肝硬化CT分级评估肝癌介入治疗肝储备功能及预后研究. 临床放射学杂志,2010,29:12.
[5] 卢东徽,郝文胜,费振乐,等. 索拉菲尼治疗19例晚期原发性肝癌临床疗效观察. 实用肝病杂志,2014,17（3）:241.
[6] Lopez PM,Villanueva A,Llovet JM. Systematic review:evidence based management of hepatocellular carcinoma—an updated analysis of randomized controlled trials. Aliment Pharmacol Ther,2006,23（11）:1535-1547.
[7] O'Neil BH,Venook AP. Hepatocellular carcinoma:the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy.Oncologist,2007,12（12）: 1425–1432.
[8] Llovet JM,Burroughs A,Bmix J. Hepatocellular carcinoma. Lancet,2003,363（9412）:898–899.
[9] Llovet JM,Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma:chemoembolization improves survival.Hepatology,2003,37（2）:429–442.
[10] Bruix J,Sala M,Llovet JM.Chemoembolization for hepatocellular carcinoma.Gastroerterology,2004,127（5）:S179–S188.
[11] Llovet JM,Real MI,Monta X,et al. Arterial embolisationor chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:a randomised controlled trial. Lancet,2002,359（9319）:1734–1739.
[12] 柴艳峰. 肝炎肝硬化患者血清总胆汁酸检测及其与肝功能分级的关系. 中国腹部疾病杂志,2001,1（3）:217-218.
[13] Llovet JM,Bmix J. Novel advancements in the management of hepatocellular carcinoma in 2008.J Hepatol,2008,48（Suppl1）:S20–S37.
[14] Raoul JL,Sangro B,Forner A, et al.Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.Cancer TreatRev,2011,37（3）:212–220.

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[3]	Zhu Yage, Liu Jinfeng.. Therapeutic efficacy of adenosine methionine and glycyrrhizin combination in treatment of patients with alcoholic cirrhosis and its effect on serum BGP levels [J]. Journal of Practical Hepatology, 2019, 22(6): 872-875.
[4]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[5]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[6]	Liu Li, Yang Lie, Chen Haiyang, et al.. Changes of hemodynamics after splenectomy combined with pericardial devascularization in patients with cirrhotic portal hypertention complicated by splenic artery steal syndrome [J]. Journal of Practical Hepatology, 2019, 22(6): 884-887.
[7]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[8]	Wang Yueyuan, Wang Yan, Zhang Dandan. Short-term efficacy of terlipressin and octreotide combination in treatment of cirrhotic patients complicated by hepatorenal syndrome [J]. Journal of Practical Hepatology, 2019, 22(5): 684-687.
[9]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[10]	Dan Zhuyongji, Liu Zhilan, Lu Yanyan, et al. Efficacy of endoscopic sequential variceal 1igation plus sclerotherapy in treatment of patients with hepatitis B-induced liver cirrhosis complicated by esophageal gastric varices bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 692-695.
[11]	Huang Hanjun, Lu Fengrong, Zhang Can. Clinical value of MRI scanning based on exchange hemodynamics model in evaluating liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 696-699.
[12]	Zhao Fangfang, Zhai Yongzhen, Feng Guohe. Efficacy and safety of autologous peripheral blood stem cell transplantation in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 700-703.
[13]	Chen Shan, Zhuang Huashuai, Xing Yixi, et al. Preventive application of meropenem in patients with liver cirrhosis complicated by upper gastrointestinal bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 704-707.
[14]	Xu Qilin, Hao Shaohuan, Ran Bo. Risk factors of portal vein thrombosis after splenectomy in patients with liver cirrhosis and portal hypertension [J]. Journal of Practical Hepatology, 2019, 22(5): 708-711.
[15]	Jin Lianghong, Li Xingjie, Guan Hongbo, et al. Clinical value of dual-energy CT iodine quantification combined with dynamic contrast-enhanced MRI in evaluating hepatic hemodynamics and liver functions in patients with hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 712-715.

Transcatheter arterial embolization in treatment of patients with primary liver cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments